Merck & Co., Inc. is a leading global biopharmaceutical company that discovers, develops, manufactures, and markets a broad range of innovative health solutions across various therapeutic areas.
An examination of the US58933YAR62 bond (CUSIP: 58933YAR6), a former corporate debt instrument issued by the globally recognized pharmaceutical giant, Merck & Co. Inc., reveals a profile characteristic of a high-quality credit investment. Merck & Co. Inc., headquartered in the United States, maintains robust credit ratings of AA- from Standard & Poor's (S&P) and A1 from Moody's, reflecting its strong financial health and capacity to meet obligations. This specific bond, denominated in USD and issued in the United States, carried a fixed annual interest rate of 2.75%, with payments distributed semi-annually to bondholders. The total issuance size for this obligation was substantial, reaching $2,500,000,000, with a minimum investment threshold set at $2,000. Originally slated to mature on September 2, 2025, this bond has successfully reached its maturity date and has been fully repaid at its par value of 100%, concluding its investment tenure.
|